Patents by Inventor Naphtali Reyna

Naphtali Reyna has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE
    Publication number: 20230159508
    Abstract: Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.
    Type: Application
    Filed: August 17, 2022
    Publication date: May 25, 2023
    Inventors: Richard T. LEWIS, Matthew HAMILTON, William J. RAY, Fernando ALVAREZ, Naphtali REYNA, Suyambu Kesava Vijayan RAMASWAMY
  • Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
    Patent number: 11173145
    Abstract: Compounds of formula (VII), which are useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase, are provided. Also provided are pharmaceutical compositions, kits comprising said compounds, and methods and uses pertaining to said compounds.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: November 16, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard T. Lewis, Matthew Hamilton, Philip Jones, Alessia Petrocchi, Naphtali Reyna, Jason Cross, Michelle Han, Michael Soth, Timothy McAfoos, Martin Tremblay
  • Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
    Patent number: 11046649
    Abstract: The present invention relates to bicyclic compounds and compositions and methods which may be useful as inhibitors of IDO1, IDO2, and TDO for the treatment or prevention of diseases such as cancer.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: June 29, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard T. Lewis, Matthew Hamilton, Philip Jones, Alessia Petrocchi, Naphtali Reyna, Timothy McAfoos, Jason Bryant Cross, Michael J. Soth
  • INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE
    Publication number: 20210154204
    Abstract: Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.
    Type: Application
    Filed: November 19, 2020
    Publication date: May 27, 2021
    Inventors: Richard T. LEWIS, Matthew HAMILTON, William J. RAY, Fernando ALVAREZ, Naphtali REYNA, Jason CROSS, Suyambu Kesava Vijayan RAMASWAMY
  • GLS1 INHIBITORS FOR TREATING DISEASE
    Publication number: 20210122744
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: July 1, 2020
    Publication date: April 29, 2021
    Inventors: Richard Thomas LEWIS, Philip JONES, Alessia PETROCCHI, Naphtali REYNA, Matthew HAMILTON, Michael J. SOTH, Timothy HEFFERNAN, Michelle HAN, Jason P. BURKE
  • INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE
    Publication number: 20210094951
    Abstract: Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.
    Type: Application
    Filed: September 8, 2020
    Publication date: April 1, 2021
    Inventors: Richard T. LEWIS, Matthew HAMILTON, William J. RAY, Fernando ALVAREZ, Naphtali REYNA, Jason CROSS, Suyambu Kesava Vijayan RAMASWAMY
  • INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE
    Publication number: 20210094921
    Abstract: Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.
    Type: Application
    Filed: September 25, 2020
    Publication date: April 1, 2021
    Inventors: Richard T. LEWIS, Matthew Michael HAMILTON, William J. RAY, Fernando ALVAREZ, Dana E. PFAFFINGER, Naphtali REYNA, Jason CROSS, Suyambu Kesava Vijayan RAMASWAMY, Nicole A. RICHARDS
  • GLS1 inhibitors for treating disease
    Patent number: 10738043
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: August 11, 2020
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard Thomas Lewis, Philip Jones, Alessia Petrocchi, Naphtali Reyna, Matthew Hamilton, Michael J. Soth, Timothy Heffernan, Michelle Han, Jason P. Burke
  • COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN DIOXYGENASE
    Publication number: 20200024236
    Abstract: The present invention relates to bicyclic compounds and compositions and methods which may be useful as inhibitors of IDO1, IDO2, and TDO for the treatment or prevention of diseases such as cancer.
    Type: Application
    Filed: July 17, 2019
    Publication date: January 23, 2020
    Inventors: Richard T. LEWIS, Matthew HAMILTON, Philip JONES, Alessia PETROCCHI, Naphtali REYNA, Timothy MCAFOOS, Jason Bryant CROSS, Michael J. SOTH
  • COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN DIOXYGENASE
    Publication number: 20190365718
    Abstract: Compounds of formula (VII), which are useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase, are provided. Also provided are pharmaceutical compositions, kits comprising said compounds, and methods and uses pertaining to said compounds.
    Type: Application
    Filed: January 16, 2018
    Publication date: December 5, 2019
    Inventors: Richard T. LEWIS, Matthew HAMILTON, Philip JONES, Alessia PETROCCHI, Naphtali REYNA, Jason CROSS, Michele HAN, Michael SOTH, Timothy MCAFOOS, Martin TREMBLAY
  • HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE
    Publication number: 20190135793
    Abstract: The present invention relates to compounds and methods useful as inhibitors of KDM5 for the treatment or prevention of cancer.
    Type: Application
    Filed: May 17, 2018
    Publication date: May 9, 2019
    Inventors: Alessia PETROCCHI, Maria Emilia DI FRANCESCO, Philip JONES, Richard Thomas LEWIS, Naphtali REYNA, Matthew HAMILTON, Michelle HAN
  • GLS1 INHIBITORS FOR TREATING DISEASE
    Publication number: 20190031651
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: October 5, 2018
    Publication date: January 31, 2019
    Inventors: Richard Thomas LEWIS, Philip JONES, Alessia PETROCCHI, Naphtali REYNA, Matthew HAMILTON, Michael J. SOTH, Timothy HEFFERNAN, Michelle HAN, Jason P. BURKE
  • GLS1 inhibitors for treating disease
    Patent number: 10125128
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: November 13, 2018
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard Thomas Lewis, Philip Jones, Alessia Petrocchi, Naphtali Reyna, Matthew Hamilton, Michael J. Soth, Timothy Heffernan, Michelle Han, Jason P. Burke
  • GLS1 INHIBITORS FOR TREATING DISEASE
    Publication number: 20170001996
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: June 30, 2016
    Publication date: January 5, 2017
    Inventors: Richard Thomas Lewis, Philip Jones, Alessia Petrocchi, Naphtali Reyna, Matthew Hamilton, Michael J. Soth, Timothy Heffernan, Michelle Han, Jason P. Burke
  • BROMODOMAIN INHIBITORS FOR TREATING DISEASE
    Publication number: 20160060260
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of bromodomain-containing protein-mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibiting activity of a bromodomain-containing protein in a human or animal subject are also provided.
    Type: Application
    Filed: August 28, 2015
    Publication date: March 3, 2016
    Applicant: Board of Regents, The University of Texas System
    Inventors: Wylie Palmer, Philip Jones, Gang Liu, Alessia Petrocchi, Naphtali Reyna, Govindan Subrumanian, Jay Theroff, Anne Yau